Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Pharmacology  





2 Side effects  





3 Legal status  





4 See also  





5 References  














THJ-2201







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


THJ-2201
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class B
  • US: Schedule I
  • Identifiers
    • [1-(5-Fluoropentyl)-1H-indazol-3-yl](1-naphthyl)methanone

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC23H21FN2O
    Molar mass360.432 g·mol−1
    3D model (JSmol)
    • c1ccc2c(c1)cccc2C(=O)c3c4ccccc4n(n3)CCCCCF

    • InChI=1S/C23H21FN2O/c24-15-6-1-7-16-26-21-14-5-4-12-20(21)22(25-26)23(27)19-13-8-10-17-9-2-3-11-18(17)19/h2-5,8-14H,1,6-7,15-16H2

    • Key:DULWRYKFTVFPTL-UHFFFAOYSA-N

    THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2][3][4]

    It is a structural analogofAM-2201 in which the central indole ring has been replaced by indazole.[5]

    Pharmacology[edit]

    THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.[6]

    Side effects[edit]

    THJ-2201 has been linked to at least one hospitalization and death due to its use.[7]

    Legal status[edit]

    Because of the hazards associated with recreational use of this compound,[8] it is classified as a Schedule I controlled substance in the United States.[9]

    It is also an Anlage II controlled drug in Germany.[10]

    See also[edit]

    References[edit]

    1. ^ Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA (January 2016). "High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes". Clinical Chemistry. 62 (1): 157–169. doi:10.1373/clinchem.2015.243535. PMID 26430074.
  • ^ Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y (September 2014). "3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures". Forensic Science International. 242: 72–80. doi:10.1016/j.forsciint.2014.06.022. PMID 25036783.
  • ^ Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T (August 2014). "Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products". Forensic Toxicology. 32 (2): 266–281. doi:10.1007/s11419-014-0238-5. S2CID 11873421.
  • ^ Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA (2016). "Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes". Forensic Toxicology. 34 (2): 256–267. doi:10.1007/s11419-016-0312-2. PMC 4971051. PMID 27547265.
  • ^ "THJ-2201". Cayman Chemical. Retrieved 21 July 2015.
  • ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
  • ^ Trecki J, Gerona RR, Schwartz MD (July 2015). "Synthetic Cannabinoid-Related Illnesses and Deaths". The New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
  • ^ Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration (December 2014). N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- indazole-3-carboxamide (AB-PINACA) and [1-(5-fluoropentyl)-1H-indazol-3- yl](naphthalen-1-yl)methanone (THJ-2201): Background Information and Evaluation of 'Three Factor Analysis' (Factors 4, 5, and 6) for Temporary Scheduling (PDF) (Report). Archived from the original (PDF) on 2018-09-27. Retrieved 2015-04-05.
  • ^ Drug Enforcement Administration Do (January 2015). "Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order". Federal Register. 80 (20): 5042–5047. PMID 25730924.
  • ^ "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)". Retrieved 9 July 2015.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=THJ-2201&oldid=1212877813"

    Categories: 
    Cannabinoids
    Designer drugs
    Organofluorides
    Naphthoylindazoles
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs missing an ATC code
    Articles containing unverified chemical infoboxes
     



    This page was last edited on 10 March 2024, at 00:21 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki